Phase 3 Arthritis, Rheumatoid trials in South Korea

Showing 1 to 25 of 73. Each trial links to its page on Pharma Observatory.

• A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis NCT06025578·Phase 3·Active, not recruiting·Bristol-Myers Squibb·Started 2023
• Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis NCT05814627·Phase 3·Completed·AbbVie·Started 2023
• MTX Hold During Covid-19 Booster NCT05313061·Phase 3·Unknown status·Seoul National University Hospital·Started 2021
• One or Two Week Methotrexate Discontinuation on Efficacy of Influenza Vaccination in Rheumatoid Arthritis. NCT05069714·Phase 3·Completed·Seoul National University Hospital·Started 2021
• Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA) NCT04333147·Phase 3·Terminated·GlaxoSmithKline·Started 2020
• Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors NCT04134728·Phase 3·Completed·GlaxoSmithKline·Started 2019
• Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs) NCT03970837·Phase 3·Terminated·GlaxoSmithKline·Started 2019
• A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX) NCT03660059·Phase 3·Completed·Astellas Pharma China, Inc.·Started 2018
• A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) NCT02955212·Phase 3·Completed·AbbVie·Started 2018
• Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis NCT03120949·Phase 3·Completed·R-Pharm International, LLC·Started 2017
• A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs NCT03086343·Phase 3·Completed·AbbVie·Started 2017
• Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis NCT03025308·Phase 3·Completed·Alfasigma S.p.A.·Started 2017
• Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease NCT02760433·Phase 3·Completed·R-Pharm International, LLC·Started 2017
• A Phase I/III Study to Evaluate Efficacy, PK and Safety Between CT-P13 SC and CT-P13 IV in Patients With Active RA NCT03147248·Phase 3·Completed·Celltrion·Started 2016
• Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate NCT02889796·Phase 3·Completed·Gilead Sciences·Started 2016
• Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy NCT02886728·Phase 3·Completed·Gilead Sciences·Started 2016
• Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment NCT02873936·Phase 3·Completed·Gilead Sciences·Started 2016
• Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease NCT02760407·Phase 3·Completed·R-Pharm International, LLC·Started 2016
• A Study to Evaluate the Long-term Safety and Efficacy of LBEC0101 in Subjects With Active RA Despite Methotrexate (MTX) NCT02715908·Phase 3·Completed·LG Life Sciences·Started 2016
• A Study Comparing LBAL to Humira® in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy NCT02746380·Phase 3·Completed·LG Life Sciences·Started 2016
• A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs NCT02706847·Phase 3·Completed·AbbVie·Started 2016
• Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis NCT02640612·Phase 3·Completed·Boehringer Ingelheim·Started 2016
• A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone NCT02675426·Phase 3·Completed·AbbVie·Started 2015
• A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate NCT02629159·Phase 3·Active, not recruiting·AbbVie·Started 2015
• Effects of Abatacept in Patients With Early Rheumatoid Arthritis NCT02504268·Phase 3·Completed·Bristol-Myers Squibb·Started 2015